EUCTR2005-005534-12-DE
Active, not recruiting
Not Applicable
randomized double blind placebo controlled study on the efficacy of autologous autovaccine in house dust mite allergy - FIAVS
The Symbio Herborn Group GmbH0 sites24 target enrollmentNovember 23, 2005
DrugsAutovaccine
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The Symbio Herborn Group GmbH
- Enrollment
- 24
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •otherwise healthy adults with house dust mite allergy prooven by positive prick test and bronchial provocation (FEV1 decrease \> 20%). Episodic bronchial asthma (GINA 0\-I°). Informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years)
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •allergies towards ingredients of the autovaccine. Bronchial asthma \> GINA I°, other chronic diseases. Pregnancy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Assessment of efficacy of lithium in prevention of peripheral neuropathyChemotherapy induce peripheral neuropathy.IRCT20160813029327N10Islamic Azad University44
Not yet recruiting
Phase 3
Comparing the use of oral misoprostol with vaginal misoprostol to facilitate spontaneous labourCTRI/2019/01/017318Fluid Research Grant
Completed
Not Applicable
Randomized double-blind placebo-controlled study of the efficacy of food containing bovine lactoferrin for suppression of colorectal polypscolorectal polyps(adenomas)JPRN-C000000182ational cancer center105
Withdrawn
Phase 2
A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjectsobesitasInsulin resistanceimpaired glucose tolerance1001842410019654NL-OMON37344Academisch Medisch Centrum20
Active, not recruiting
Phase 1
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”EUCTR2018-004705-26-ESSanofi Aventis Groupe188